We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to McKesson (MCK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect McKesson (MCK - Free Report) to post quarterly earnings of $11.56 per share in its upcoming report, which indicates a year-over-year increase of 14.2%. Revenues are expected to be $101.92 billion, up 12.2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenue- North American Pharmaceutical' to reach $84.12 billion. The estimate indicates a change of +1.2% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Medical-Surgical Solutions' of $2.94 billion. The estimate points to a change of +3% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Prescription Technology Solutions' reaching $1.47 billion. The estimate suggests a change of +9.8% year over year.
Based on the collective assessment of analysts, 'Adjusted Operating Profit- Medical-Surgical Solutions' should arrive at $284.53 million. The estimate is in contrast to the year-ago figure of $285.00 million.
The combined assessment of analysts suggests that 'Adjusted Operating Profit- North American Pharmaceutical' will likely reach $991.34 million. The estimate is in contrast to the year-ago figure of $1.05 billion.
Analysts predict that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $310.20 million. The estimate compares to the year-ago value of $285.00 million.
Over the past month, McKesson shares have recorded returns of -8% versus the Zacks S&P 500 composite's +10% change. Based on its Zacks Rank #3 (Hold), MCK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Countdown to McKesson (MCK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect McKesson (MCK - Free Report) to post quarterly earnings of $11.56 per share in its upcoming report, which indicates a year-over-year increase of 14.2%. Revenues are expected to be $101.92 billion, up 12.2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenue- North American Pharmaceutical' to reach $84.12 billion. The estimate indicates a change of +1.2% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Medical-Surgical Solutions' of $2.94 billion. The estimate points to a change of +3% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- Prescription Technology Solutions' reaching $1.47 billion. The estimate suggests a change of +9.8% year over year.
Based on the collective assessment of analysts, 'Adjusted Operating Profit- Medical-Surgical Solutions' should arrive at $284.53 million. The estimate is in contrast to the year-ago figure of $285.00 million.
The combined assessment of analysts suggests that 'Adjusted Operating Profit- North American Pharmaceutical' will likely reach $991.34 million. The estimate is in contrast to the year-ago figure of $1.05 billion.
Analysts predict that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $310.20 million. The estimate compares to the year-ago value of $285.00 million.
View all Key Company Metrics for McKesson here>>>Over the past month, McKesson shares have recorded returns of -8% versus the Zacks S&P 500 composite's +10% change. Based on its Zacks Rank #3 (Hold), MCK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .